Heritage Investors Management Corp Cuts Stake in Zimmer Biomet Holdings, Inc. $ZBH

Heritage Investors Management Corp lowered its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.1% during the 1st quarter, Holdings Channel.com reports. The firm owned 126,959 shares of the medical equipment provider’s stock after selling 6,886 shares during the quarter. Heritage Investors Management Corp’s holdings in Zimmer Biomet were worth $11,480,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Main Management ETF Advisors LLC boosted its position in Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after buying an additional 112 shares during the period. Boltwood Capital Management grew its stake in shares of Zimmer Biomet by 3.9% during the fourth quarter. Boltwood Capital Management now owns 3,866 shares of the medical equipment provider’s stock valued at $348,000 after buying an additional 144 shares during the last quarter. Independence Bank of Kentucky increased its holdings in shares of Zimmer Biomet by 9.7% in the fourth quarter. Independence Bank of Kentucky now owns 1,633 shares of the medical equipment provider’s stock worth $147,000 after buying an additional 145 shares during the period. LOM Asset Management Ltd lifted its stake in shares of Zimmer Biomet by 21.5% in the 4th quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock valued at $75,000 after acquiring an additional 147 shares during the last quarter. Finally, Oppenheimer & Co. Inc. lifted its stake in shares of Zimmer Biomet by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock valued at $1,831,000 after acquiring an additional 152 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $87.50 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The firm has a market cap of $16.93 billion, a P/E ratio of 22.73, a P/E/G ratio of 2.48 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29. The firm has a 50-day moving average of $86.20 and a 200-day moving average of $89.83.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. During the same quarter in the prior year, the company posted $1.81 EPS. Zimmer Biomet’s quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Analysts Set New Price Targets

Several brokerages recently weighed in on ZBH. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Barclays lowered their price objective on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Citizens Jmp cut their target price on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a report on Wednesday, April 29th. Finally, Wells Fargo & Company decreased their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $102.70.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.